Showing 1,421 - 1,440 results of 101,676 for search '(( 5 ((nn decrease) OR (a decrease)) ) OR ( 5 ((non decrease) OR (mean decrease)) ))', query time: 1.92s Refine Results
  1. 1421
  2. 1422
  3. 1423
  4. 1424
  5. 1425
  6. 1426
  7. 1427
  8. 1428

    Human preterm infants diagnosed with IUGR have decreased Paneth cell counts compared to preterm non-IUGR control infants. by Camille M. Fung (844334)

    Published 2016
    “…(A) IUGR infants had similar numbers of goblet cells per 100 epithelial cells compared to non-IUGR infants (p = 0.5). …”
  9. 1429
  10. 1430

    Retinoschisin secretion into the conditioned medium is decreased by addition of taxol. by Eiko Kitamura (349087)

    Published 2013
    “…Retinoschisin secretion into the medium decreases in a dose-dependent manner between 0.5 µM and 10 µM taxol. …”
  11. 1431

    Decreased HIF levels associated with hyperoxic cell state. by Julie M. Koeman (108185)

    Published 2008
    “…<p>(A) Normalized densitometry of HIF-1α protein levels (•),HIF-1β protein levels (▴), and HIF-1 DNA-binding activity (⧫) as presented in <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1000176#pgen-1000176-g005" target="_blank">Figure 5B</a> of the Jiang et al. article. …”
  12. 1432

    ANG II treatment leads to decreased contractile function. by Renita E. Horton (847891)

    Published 2016
    “…(E) Representative stress traces generated from x-projections of films (F) ANG II treatment leads to a decrease in contractile stress generation. Control n = 85 tissues, 5 nM n = 15 tissues, 100 nM n = 69 tissues, 3 harvests. …”
  13. 1433
  14. 1434

    EGCG decreases RSK2-mediated cell viability. by Hanyong Chen (320863)

    Published 2015
    “…Differences were evaluated using the Student’s t-test and the asterisk (*) indicates a significant decrease in viability in RSK2<sup>+/+</sup> MEFs compared to RSK2<sup>-/-</sup> MEFs (<i>p</i> < 0.05).…”
  15. 1435
  16. 1436
  17. 1437
  18. 1438
  19. 1439

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

    Published 2025
    “…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
  20. 1440